Formulary Chapter 7: Obstetrics, Gynaecology, and urinary-tract disorders - Full Chapter
|
07.04.05 |
Drugs for erectile dysfunction |
|
|
07.04.05 |
Phosphodiesterase type 5 inhibitors |
|
|
07.04.05 |
Papaverine and phentolamine |
|
|
Aviptadil + phentolamine
(Invicorp®)
|
Restricted

|
Erectile dysfunction in men who have failed to respond to oral PDE5i (sildenafil and tadalafil) and intracavernosal/urethral alprostadil. Secondary care initiation, primary care continuation (SLS only) (JFC November 2017) Provider notes - NMUH:
- To be prescribed by Urology Consultants ONLY. To be used as a second line option after treatment failure or intolerance with oral PDE5i (tadalafil or sildenafil) and intracavernosal/ urethral alprostadil.
- RFL:
- RNOH:
- UCLH:
- WH:
- Approved by NCL as 2nd line treatment for erectile dysfuntion if alprostadil fails (JFC November 2016)
|
Key |
Traffic Light Status Information
Status |
Description |
 
|
Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.
Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.
Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity. |
 
|
Medicines which should normally be prescribed by specialists only (hospital only).
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf |
 
|
Medicines not recommended for routine use in primary or secondary care.
Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data. |
|
|